Crossmark

Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study

Crossref DOI link: https://doi.org/10.1186/s10194-019-0973-4

Published Online: 2019-03-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heinskou, Tone Bruvik http://orcid.org/0000-0002-1318-4262
Maarbjerg, Stine

Wolfram, Frauke

Rochat, Per

Brennum, Jannick

Olesen, Jes

Bendtsen, Lars
Funding

Funding for this research was provided by:

Trigeminus Foreningen
License Information

Text and Data Mining valid from 2019-03-04
More Information

Article History

Received: 21 January 2019

Accepted: 18 February 2019

First Online: 4 March 2019

Ethics approval and consent to participate

: The Danish National Committee on Health Research Ethics confirmed that the project did not need ethical approval and that patients consent was not required as it is a non-interventional observational study, ID number H-1-2012-093. STROBE reporting guidelines [CitationRef removed] were used as the checklist for the reporting of our findings.

: Not applicable.

: Lars Bendtsen (LB): Within the last 3 years LB has served on the scientific advisory board for Novartis, Allergan and Biogen, has been principal investigator for Biogen, and has given lectures for Allergan, Novartis and Teva.All authors but Lars Bendtsen, declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.TH, SM, PR, FW, JB and JO authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.